Purpose: Testosterone is the recommended treatment for transgender youth who desire the development of male secondary sexual characteristics. While intramuscular injection remains the most common means of delivering injectable testosterone, subcutaneous (SC) delivery has been used with clinical success. No data reporting serum levels and feasibility are available. We aimed to determine both if subcutaneous delivery of testosterone resulted in menstrual cessation, and the normal male ranges of serum testosterone in this subpopulation of female-to-male transgender youth.
Methods: Within an urban hospital-affiliated Adolescent Medicine clinic, thirty-six youth aged 13 to 24 years transitioning from female to male received testosterone cypionate via subcutaneous injections for masculinization. Participants were a subpopulation of those enrolled in a longitudinal, prospective study examining the impact of treatment for transgender youth. A titrated dose of testosterone cypionate (average dose 46.4 mg per week) via subcutaneous injection was delivered over 6 months. The main outcomes included menstrual cessation as well as raised free and total testosterone levels.
Results: Eighty-five percent of participants had ceased menstrual bleeding within 6 months after initiating testosterone. The average time to menstrual cessation was 2.9 months. Most participants (91.4%) reached total testosterone levels within the normal male range after 6 months of subcutaneous delivery (49-1138 ng/dL, 521.4 ng/dL total test). Few adverse effects were reported.
Conclusion: Subcutaneous delivery of testosterone for masculinization of transgender youth seems to be effective and well tolerated over short treatment times. Additional studies are needed to determine whether long term use of subcutaneous testosterone delivery yield similar results.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1089/lgbt.2014.0018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A KIF20A-based thermosensitive hydrogel vaccine effectively potentiates immune checkpoint blockade therapy for hepatocellular carcinoma.
NPJ Vaccines
January 2025
First Department of Hepatobiliary Surgery, General Surgery Center, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Hepatocellular carcinoma (HCC) is a highly prevalent malignancy with limited treatment efficacy despite advances in immune checkpoint blockade (ICB) therapy. The inherently weak immune responses in HCC necessitate novel strategies to improve anti-tumor immunity and synergize with ICB therapy. Kinesin family member 20A (KIF20A) is a tumor-associated antigen (TAA) overexpressed in HCC, and it could be a promising target for vaccine development.
View Article and Find Full Text PDFUnintentional exposure to leuprolide acetate during early pregnancy with a huge intramural myoma.
BMJ Case Rep
January 2025
Department of Medicine, University of Hawai'i at Mānoa John A Burns School of Medicine, Honolulu, Hawaii, USA.
Leuprolide acetate is commonly used to reduce the size of myomas before surgery. Initially, it stimulates pituitary gonadotropin secretion, followed by sustained suppression of gonadal function. However, the impact on pregnancy outcomes from inadvertent exposure remains unclear.
View Article and Find Full Text PDFDevelopment of a Thermoresponsive Core-Shell Hydrogel for Sequential Delivery of Antibiotics and Growth Factors in Regenerative Endodontics.
Front Biosci (Elite Ed)
October 2024
Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, 1983969411 Tehran, Iran.
Background: Regenerative endodontics requires an innovative delivery system to release antibiotics/growth factors in a sequential trend. This study focuses on developing/characterizing a thermoresponsive core-shell hydrogel designed for targeted drug delivery in endodontics.
Methods: The core-shell chitosan-alginate microparticles were prepared by electrospraying to deliver bone morphogenic protein-2 for 14 days and transforming growth factor-beta 1 (TGF-β1) for 7-14 days.
Size-dependent Nanoparticle Accumulation In Venous Malformations.
J Vasc Anom (Phila)
December 2024
Laboratory for Biomaterials and Drug Delivery, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
Objective: The current treatment of venous malformations (VMs) consists of medications with systemic toxicity and procedural interventions with high technical difficulty and risk of hemorrhage. Using nanoparticles (NPs) to enhance drug delivery to VMs could enhance efficacy and decrease systemic toxicity. NPs can accumulate in tissues with abnormal vasculature, a concept known as the enhanced permeation and retention (EPR) effect.
View Article and Find Full Text PDFNanoparticle and microparticle-based systems for enhanced oral insulin delivery: A systematic review and meta-analysis.
J Nanobiotechnology
December 2024
Departamento de Farmacia, Facultad de Química, Universidad Nacional Autónoma de México, 04510, Ciudad de Mexico, Mexico.
Diabetes mellitus (DM) prevalence is rising worldwide. Current therapies comprising subcutaneous insulin injections can cause adverse effects such as lipodystrophy, local reactions like redness and swelling, fluid retention, and allergic reactions. Nanoparticle carriers for oral insulin are groundbreaking compared to existing methods because they are non-invasive treatments, showing operational convenience, controlled release profile, and ability to simulate the physiological delivery route into the bloodstream.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!